Latest Conference Articles

Single-Agent Lenvatinib Shows Real-World Efficacy in Frontline HCC

Single-Agent Lenvatinib Shows Real-World Efficacy in Frontline HCC

January 16th 2021, 7:11pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Mean Daily Step Count While Receiving SM-88 Correlates With Patient-Reported QoL in Metastatic Pancreatic Cancer

Mean Daily Step Count While Receiving SM-88 Correlates With Patient-Reported QoL in Metastatic Pancreatic Cancer

January 16th 2021, 6:56pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

Addition of Pembrolizumab to Chemo Does Not Negatively Impact QoL in Patients With Esophageal Cancer

Addition of Pembrolizumab to Chemo Does Not Negatively Impact QoL in Patients With Esophageal Cancer

January 16th 2021, 6:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Health-related quality of life during an 18-week period proved to be similar over for patients with esophageal cancer treated with either pembrolizumab or placebo added to chemotherapy.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021, 4:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

ASCO GI 2021 News

ASCO GI 2021 News

January 16th 2021, 3:15pm

OncLive® will be LIVE with OncLive® News Network: On Location at the virtual 2021 ASCO GI. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented in gastrointestinal cancer during the virtual conference.

Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16th 2021, 3:30am

Gastrointestinal Cancers Symposium (ASCO GI)

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

January 15th 2021, 10:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

Health-Related Quality of Life Scores in Young CRC Survivors Are Low and Require Targeted Intervention

Health-Related Quality of Life Scores in Young CRC Survivors Are Low and Require Targeted Intervention

January 15th 2021, 9:45pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021, 9:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer.

x